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Abstract
4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs were designed, synthesized, and evaluated
for cytotoxic activity. Among all 4-substituted ABO analogs, cyclohexyl (12), N-methoxy-N-
methylacetamide (14), and various aromatic derivatives (15-25 and 27) exhibited promising cell
growth inhibitory activity with ED50 values of 0.01-2.1 μM against all tested tumor cell lines. The
4′-methoxyphenyl derivative (18) and 3′-methylphenyl derivative (24) showed the most potent
antitumor activity against a broad range of cancer cell lines with ED50 values of 0.01-0.17 μM.
Preliminary SAR results indicated that substitutions on nitrogen are critical to the antitumor
potency.
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Natural products have been one of the most significant sources for drugs and drug leads.1-3
In 2004, our group isolated a new compound, neo-tanshinlactone (1, Figure 1),4, 5 that
showed potent anti-breast cancer activity. Our recent results proved that 4-ethyl neo-
tanshinlactone (2) is a selective and potent in vivo anti-breast cancer agent in three different
mouse models.6 In order to study the contribution of the individual rings of 1 and improve
its pharmacological properties, we designed five different scaffolds, which led to the
discovery and development of three series of novel anti-cancer agents: 2-(furan-2-
yl)naphthalen-1-ol (FNO), 6-aryl-4H-furo [3,2-c]pyran-4-one (AFPO), and
tetrahydronaphthalene-1-ol (TNO) derivatives.7-9 The promising results and useful
information we obtained from these studies encouraged us to design and develop additional
novel anti-cancer agents based on 1.
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Structural simplification and bio-isosteric replacement are powerful and highly productive
tools for analog design and drug development.10 In our continuing studies, we combined
these two strategies to further explore the structure of 1 and develop more potent analogs.
Previously, we designed a simplified scaffold 3 by breaking the furan ring-D (Figure 1);7
however, this compound series did not show significant anti-cancer activity. We then
designed scaffold 4 (ABO), by replacing the oxygen in 3 with nitrogen. Braccio et al.
reported numerous pyran derivatives, including four compounds with this scaffold, which
showed activity against Ehrlich ascites tumor cells.11 These positive results supported our
design and investigation of this scaffold. We introduced different substituent groups around
the skeleton of 4 to establish preliminary SAR and develop more potent analogs. Because
our prior study showed that 2-analogs with an ethyl group at the C-4 position possessed
much higher potency than 1-analogs with a hydrogen at the same position (Figure 1), we
also evaluated the effect of an ethyl group (R1=Et) in the corresponding position (C-7) in 4.
This paper reports the synthesis of novel ABO analogs, discovery of new analogs with
potent antitumor activity, and identification of preliminary SAR.
All target compounds 9-31 were synthesized from 4-hydroxybenzochromenones 5 and 6
(Scheme 1).4 Treatment of 5 and 6 with POCl3 afforded the related chlorides 7 and 8,
respectively.11 Differently substituted amino groups were then incorporated to study the
effect of position, hydrogen bond donor or acceptor, and group size. Compounds, 9-10,
13-14, and 16-31 were newly prepared by substitution reaction of the chloride in 6 or 7 with
various amines according to reported procedures.11, 12 Compounds 11, 12, and 15 were
previously synthesized by Braccio’s group.11
All synthesized analogs 9-31 were tested for in vitro cytotoxic activity against a panel of
human tumor cell lines according to previously published methods (Table 1).7 Cell lines
included A549 (non small cell lung cancer), DU145 (prostate cancer cell line), KB
(nasopharyngeal carcinoma), and KB-vin (vincristine-resistant MDR KB subline), MDA-
MB-231 (estrogen receptor negative breast cancer), SK-BR-3 (estrogen receptor negative,
HER2 over-expressing breast cancer), ZR-75-1 (estrogen receptor positive breast cancer).
While the parent compound, 1, displayed selective activity against SK-BR-3 and ZR-7-51
breast cancer cell lines, ABO analogs showed a broad activity spectrum against all seven
cancer cell lines tested.
Concerning analogs with aliphatic R2/R3 amino substituents, 12 with a cyclohexyl group
showed much higher activity than the methyl, propyl, and cyclopropyl derivatives 9-11,
which suggested a bulky amino group is favored. The tertiary amines 28-30 were essentially
inactive; thus, the secondary amine could play a critical role in the antitumor activity. The
NH might act as a hydrogen bond donor, which can be important to ligand-receptor
interaction. Compounds 14 with an N-methoxy-N-methylacetamide group and 13 methyl
acetate group were between 3- and 60-fold more potent depending on the cell lines tested,
respectively, than 10 with a propyl group. These results suggested that a hydrogen bond
acceptor may be favored in this side chain.
Concerning aromatic R2/R3 substitutents, most aromatic derivatives, regardless of the
position and type of functional group on the phenyl ring, showed significant cytotoxicity
with ED50 values of 0.01-2.1 μM. The only exception was the 3′-Br analog, 26, which
dramatically lost inhibitory activity and suggested that halogen may not be favored at this
position. Among all aromatic derivatives, 15-27, 4′-MeO analog 18 and 3′-Me analog 24
were the most potent against all tested tumor cell lines (ED50 values of 0.01-0.17 μM).
Naphthyl analog 27 also displayed potent activity (ED50 = 0.27-0.53 μM). These results may
indicate that an aromatic group is suitable to fit into the binding pocket of the target protein,
resulting in potent activity.
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We also investigated the difference between hydrogen and ethyl as the R1 substituent by
comparison of 14 and 31, respectively. Compound 14 was 5- to 38-fold more potent than the
related R1-ethyl analog, 31. Thus, hydrogen is favored over ethyl in ring-A, which contrasts
with the SAR of 1-analogs. Moreover, 14 displayed broader antitumor activity compared
with 1, which could suggest a different mechanism of action. Interestingly, analog 30
showed unique selective activity against the ZR-75-1 cell line (ED50 = 3.9 μM) compared
with other tested cell lines (ED50 > 30 μM).
In conclusion, we designed 4-amino-2H-benzo[h]chromen-2-one (ABO) analogs by
structural simplification and bio-isosteric replacement of neo-tanshinlactone (1), and
investigated in vitro antitumor activity. The results indicated that ring-D of 1 is critical to
both potency and tumor-tissue selectivity. Based on this study, a novel class of anti-cancer
agents, ABO derivatives, was discovered and preliminary SAR around this scaffold was
established as follows: (1) secondary amine (R2 or R3 = H) is preferred over tertiary amine
(R2 and R3 ≠ H); (2) bulky groups are favored at R2/R3 position; (3) 3′-bromo phenyl group
can cause dramatic loss of potency and (4) at R1 position, a hydrogen is better than an ethyl
group. Compounds 18 and 24 were the most potent analogs (ED50 values of 0.01 and 0.08
μM, respectively, against the ZR-7-51 cell line), and showed broader antitumor activity
compared with 1. Mechanism of action studies are ongoing and progress will be reported in
due course. In summary, 18 and 24 are promising new lead compounds for further
development toward a potential clinical trials candidate.
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Structures of neo-tanshinlactone (1), 4-ethyl neo-tanshinlactone (2), previously reported
scaffold 3, and newly designed scaffold 4
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Reagents and conditions: (a) POCl3, Et3N, reflux, 1h; (b) aliphatic amines, EtOH, reflux, 2h;
(c) 2-amino-N-methoxy-N-methylacetamide hydrobromide, Et3N, EtOH, 55 °C; (d)
aromatic amines, ethylene glycol, 160 °C, 1h.
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